Health
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment – MD Linx
MDLinx original journal summary on Lung Cancer, Oncology from Lung Cancer
Researchers assessed efficacy of osimertinib-based combination therapies in non-small cell lung cancer (NSCLC) patients harbouring
T790M mutations who developed progressive disease following treatment with osimertinib. Participants were NSCLC patients…
Continue Reading
-
Noosa News17 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General13 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News22 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News15 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia